2 Information about brigatinib

Information about brigatinib

Marketing authorisation indication

Brigatinib (Alunbrig, Takeda) has a marketing authorisation for 'the treatment of adult patients with anaplastic lymphoma kinase (ALK)‑positive advanced non-small-cell lung cancer previously treated with crizotinib'.

Dosage in the marketing authorisation

The recommended starting dosage of brigatinib is 90 mg once daily for the first 7 days, then 180 mg once daily. Treatment should continue as long as there is clinical benefit.

If brigatinib treatment is interrupted for 14 days or longer for reasons other than adverse reactions, treatment should be resumed at 90 mg once daily for 7 days before increasing to the previously tolerated dose.

If a dose is missed or vomiting occurs after taking a dose, an additional dose should not be administered, and the next dose should be taken at the scheduled time.


The proposed list price for brigatinib is:

£4,900 for 28×180 mg tablets (the recommended dose), £4,900 for a starter pack (7×90 mg plus 21×180 mg tablets), £3,675 for 28×90 mg tablets, £1,225 for 28×30 mg tablets (company submission).

The company has a commercial arrangement. This makes brigatinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)